J M Davis

Summary

Affiliation: University of Illinois at Chicago
Country: USA

Publications

  1. ncbi request reprint Old versus new: weighing the evidence between the first- and second-generation antipsychotics
    John M Davis
    Department of Psychiatry M C 912, University of Illinois at Chicago, University of Maryland Psychiatric Research Center, 1601 W Taylor Street, Chicago, IL, USA
    Eur Psychiatry 20:7-14. 2005
  2. ncbi request reprint American College of Neuropsychopharmacology--43rd annual meeting. 12-16 December 2004, San Juan, Puerto Rico
    John M Davis
    Illinois State Psychiatric Institute, Room 309, 1601 West Taylor Street, West Chicago, IL 60612 4397, USA
    IDrugs 8:100-3. 2005
  3. ncbi request reprint Dose response and dose equivalence of antipsychotics
    John M Davis
    Department of Psychiatry, The Psychiatric Institute, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Clin Psychopharmacol 24:192-208. 2004
  4. ncbi request reprint A meta-analysis of the efficacy of second-generation antipsychotics
    John M Davis
    Psychiatric Institute, University of Illinois at Chicago, 60612, USA
    Arch Gen Psychiatry 60:553-64. 2003
  5. pmc Commentary on strategies for switching antipsychotics
    John M Davis
    Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL 60612, USA
    BMC Med 6:18. 2008
  6. ncbi request reprint The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials
    J M Davis
    Department of Psychiatry and the Psychiatric Institute, University of Illinois at Chicago, USA
    J Clin Psychiatry 62:757-71. 2001
  7. ncbi request reprint Choice of maintenance medication for schizophrenia
    John M Davis
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 60612, USA
    J Clin Psychiatry 64:24-33. 2003
  8. pmc Should we treat depression with drugs or psychological interventions? A reply to Ioannidis
    John M Davis
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA
    Philos Ethics Humanit Med 6:8. 2011
  9. ncbi request reprint Clinical profile of an atypical antipsychotic: risperidone
    John M Davis
    The Psychiatric Institute, University of Illinois at Chicago, 60612, USA
    Schizophr Bull 28:43-61. 2002
  10. pmc In psychosis, cortical interneurons overexpress DNA-methyltransferase 1
    Marin Veldic
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois, 1601 West Taylor Street, Chicago, IL 60612, USA
    Proc Natl Acad Sci U S A 102:2152-7. 2005

Detail Information

Publications64

  1. ncbi request reprint Old versus new: weighing the evidence between the first- and second-generation antipsychotics
    John M Davis
    Department of Psychiatry M C 912, University of Illinois at Chicago, University of Maryland Psychiatric Research Center, 1601 W Taylor Street, Chicago, IL, USA
    Eur Psychiatry 20:7-14. 2005
    ..Choice of antipsychotic, in our opinion, is probably the most important decision that the clinician makes for the psychotic patient. This involves the choice of drug, its dose, balancing efficacy, side-effects and cost...
  2. ncbi request reprint American College of Neuropsychopharmacology--43rd annual meeting. 12-16 December 2004, San Juan, Puerto Rico
    John M Davis
    Illinois State Psychiatric Institute, Room 309, 1601 West Taylor Street, West Chicago, IL 60612 4397, USA
    IDrugs 8:100-3. 2005
  3. ncbi request reprint Dose response and dose equivalence of antipsychotics
    John M Davis
    Department of Psychiatry, The Psychiatric Institute, University of Illinois at Chicago, Chicago, IL 60612, USA
    J Clin Psychopharmacol 24:192-208. 2004
    ..3 to 10 mg). While high-dose FGAs are not less effective, we feel it is important not to avoid using high dose to avoid excessive toxicity...
  4. ncbi request reprint A meta-analysis of the efficacy of second-generation antipsychotics
    John M Davis
    Psychiatric Institute, University of Illinois at Chicago, 60612, USA
    Arch Gen Psychiatry 60:553-64. 2003
    ....
  5. pmc Commentary on strategies for switching antipsychotics
    John M Davis
    Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor Street, Chicago, IL 60612, USA
    BMC Med 6:18. 2008
    ..In this issue, Ganguli et al. have carried out a randomized switching study, the data from which indicates the tactics that might be optimal. We put this paper into context, provide a critique and describe indications for switching...
  6. ncbi request reprint The effects of olanzapine on the 5 dimensions of schizophrenia derived by factor analysis: combined results of the North American and international trials
    J M Davis
    Department of Psychiatry and the Psychiatric Institute, University of Illinois at Chicago, USA
    J Clin Psychiatry 62:757-71. 2001
    ..The choice of drug to treat a patient with schizophrenia is one of the most critical clinical decisions. Controversy exists on the differential efficacy of olanzapine...
  7. ncbi request reprint Choice of maintenance medication for schizophrenia
    John M Davis
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 60612, USA
    J Clin Psychiatry 64:24-33. 2003
    ....
  8. pmc Should we treat depression with drugs or psychological interventions? A reply to Ioannidis
    John M Davis
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, Chicago, IL, USA
    Philos Ethics Humanit Med 6:8. 2011
    ....
  9. ncbi request reprint Clinical profile of an atypical antipsychotic: risperidone
    John M Davis
    The Psychiatric Institute, University of Illinois at Chicago, 60612, USA
    Schizophr Bull 28:43-61. 2002
    ..Second, we performed a meta-analysis of 18 controlled risperidone trials: risperidone was consistently more effective than conventional antipsychotics in treating positive and negative symptoms...
  10. pmc In psychosis, cortical interneurons overexpress DNA-methyltransferase 1
    Marin Veldic
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois, 1601 West Taylor Street, Chicago, IL 60612, USA
    Proc Natl Acad Sci U S A 102:2152-7. 2005
    ..Interestingly, the DNMT1 increase failed to occur when patients with psychosis received a combination of valproate and APS treatment but not APS monotherapy...
  11. ncbi request reprint GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon
    Alessandro Guidotti
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 Taylor St, Chicago, IL 60612, USA
    Psychopharmacology (Berl) 180:191-205. 2005
    ..Indirectly, this GABAergic neuron downregulation may play a key role in the expression of positive and negative symptoms of SZ and BP disorders...
  12. ncbi request reprint S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis
    Alessandro Guidotti
    Department of Psychiatry, Psychiatric Institute, University of Illinois, Chicago, Illinois, USA
    Neuroreport 18:57-60. 2007
    ....
  13. ncbi request reprint A double-blind, randomized, prospective evaluation of the efficacy and safety of risperidone versus haloperidol in the treatment of schizoaffective disorder
    P G Janicak
    The Psychiatric Clinical Research Center and Department of Psychiatry, College of Medicine, University of Illinois at Chicago, 60612, USA
    J Clin Psychopharmacol 21:360-8. 2001
    ..In those subjects with higher baseline HAM-D scores (i.e., >20), risperidone produced a greater improvement in depressive symptoms than haloperidol...
  14. doi request reprint Epigenetic GABAergic targets in schizophrenia and bipolar disorder
    A Guidotti
    Department of Psychiatry, University of Illinois at Chicago, College of Medicine, Psychiatric Institute, 1601 Taylor, Chicago, IL 60612, USA
    Neuropharmacology 60:1007-16. 2011
    ..This article is part of a Special Issue entitled 'Trends in neuropharmacology: in memory of Erminio Costa'...
  15. pmc Lower number of cerebellar Purkinje neurons in psychosis is associated with reduced reelin expression
    Ekrem Maloku
    Department of Psychiatry, Psychiatric Institute, University of Illinois, Chicago, IL 60612, USA
    Proc Natl Acad Sci U S A 107:4407-11. 2010
    ..This finding suggests that lack of reelin impairs GABAergic Purkinje neuron expression and/or positioning during cerebellar development...
  16. ncbi request reprint A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia
    John M Kane
    Department of Psychiatry, Hillside Hospital, Glen Oaks, NY 11004, USA
    Am J Psychiatry 159:554-60. 2002
    ..Maintenance medication is critical in the prevention of psychotic relapse and rehospitalization among patients with schizophrenia. Given potential adverse effects, identification of the minimum effective dose is clinically important...
  17. ncbi request reprint A comparison of thiothixene with chlorpromazine in the treatment of mania
    P G Janicak
    Illinois State Psychiatric Institute, Chicago
    J Clin Psychopharmacol 8:33-7. 1988
    ..The implications for less aggressive use of neuroleptics to treat mania are discussed...
  18. pmc A decrease of reelin expression as a putative vulnerability factor in schizophrenia
    F Impagnatiello
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois, Chicago, IL 60612, USA
    Proc Natl Acad Sci U S A 95:15718-23. 1998
    ..These findings are interpreted within a neurodevelopmental/vulnerability "two-hit" model for the etiology of schizophrenia...
  19. pmc An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes
    A Zhubi
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois at Chicago, IL, USA
    Schizophr Res 111:115-22. 2009
    ..Hence, PBL studies may become useful to investigate a diagnostic epigenetic marker of SZ morbidity...
  20. pmc Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder
    Marin Veldic
    Psychiatric Institute, Department of Psychiatry, College of Medicine, University of Illinois, 1601 West Taylor Street, Chicago, IL 60612, United States
    Schizophr Res 91:51-61. 2007
    ..This suggests that different epigenetic mechanisms must exist in the pathogenesis underlying SZ and BDP and implies that these disorders might involve two separate entities that are characterized by a well-defined neuropathology...
  21. pmc L-methionine decreases dendritic spine density in mouse frontal cortex
    Patricia Tueting
    Department of Psychiatry, Psychiatric Institute, College of Medicine, University of Illinois at Chicago, USA
    Neuroreport 21:543-8. 2010
    ....
  22. ncbi request reprint Imidazenil: an antagonist of the sedative but not the anticonvulsant action of diazepam
    James Auta
    Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 West Taylor St, Chicago, IL 60612, USA
    Neuropharmacology 49:425-9. 2005
    ..Thus, we suggest that imidazenil might be more effective than FLU at alleviating the withdrawal syndrome associated with long-term BZ administration...
  23. doi request reprint Effects of olanzapine and risperidone on lipid metabolism in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized five month study
    Robert C Smith
    Department of Psychiatry, New York University Medical School, Hewlett, NY 11557, USA
    Schizophr Res 120:204-9. 2010
    ..We present results of a randomized prospective study of lipid metabolism and metabolic syndrome in chronic schizophrenic patients using both fasting and post-prandial lipid measures...
  24. ncbi request reprint Reelin down-regulation in mice and psychosis endophenotypes
    Patricia Tueting
    Psychiatric Institute, University of Illinois at Chicago, 1601 West Taylor Street Chicago, IL 60612, USA
    Neurosci Biobehav Rev 30:1065-77. 2006
    ..Thus, an animal model that combines genetic heterozygocity with epigenesis holds promise for understanding the role of Reelin down-regulation in psychosis...
  25. ncbi request reprint Issues that may determine the outcome of antipsychotic trials: industry sponsorship and extrapyramidal side effect
    John M Davis
    Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, IL 60612, USA
    Neuropsychopharmacology 33:971-5. 2008
    ..We were unable to confirm that the drug's EPS properties or antiparkinsonian management altered actual efficacy...
  26. pmc Methodological factors influencing measurement and processing of plasma reelin in humans
    Giovanni Lugli
    Department of Psychiatry and Psychiatric Institute, University of Illinois at Chicago, MC 912, 1601 W, Taylor Street, Chicago, IL 60612, USA
    BMC Biochem 4:9. 2003
    ..Here we describe the methodological and biological foundation for carrying out and interpreting clinical studies of plasma reelin...
  27. pmc Olfactory discrimination training up-regulates and reorganizes expression of microRNAs in adult mouse hippocampus
    Neil R Smalheiser
    Department of Psychiatry and UIC Psychiatric Institute MC912, University of Illinois at Chicago, 1601 W Taylor Street, Chicago, IL 60612, USA
    ASN Neuro 2:e00028. 2010
    ..These in vivo results indicate that significant, dynamic and co-ordinated changes in miRNA expression accompany early stages of learning...
  28. doi request reprint Another view of the history of antipsychotic drug discovery and development
    W T Carpenter
    Department of Psychiatry, Maryland Psychiatric Research Center, University of Maryland School of Medicine, Baltimore, MD, USA
    Mol Psychiatry 17:1168-73. 2012
    ..New clinical and basic neuroscience paradigms may guide the near future and provide a more heuristic construct for novel and innovative discovery...
  29. ncbi request reprint Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study
    A Guidotti
    Psychiatric Institute, University of Illinois at Chicago, 1601 W Taylor St, Room 256, Chicago, IL 60612, USA
    Arch Gen Psychiatry 57:1061-9. 2000
    ....
  30. pmc Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research
    Robert P McMahon
    Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland Baltimore Medical School, Baltimore, MD, USA
    Schizophr Bull 34:292-301. 2008
    ..Shortening placebo-controlled trials would reduce patient burden and ethical objections to prolonged administration of placebo and reduce potential bias due to high dropout rates in longer clinical trials...
  31. doi request reprint Effects of olanzapine and risperidone on glucose metabolism and insulin sensitivity in chronic schizophrenic patients with long-term antipsychotic treatment: a randomized 5-month study
    Robert C Smith
    Department of Psychiatry, NYU Medical School, Hewlett, NY 11557, USA
    J Clin Psychiatry 70:1501-13. 2009
    ..Randomized prospective studies of metabolic effects during treatment with these drugs may provide results that are more informative...
  32. ncbi request reprint Structure of mania: depressive, irritable, and psychotic clusters with different retrospectively-assessed course patterns of illness in randomized clinical trial participants
    A C Swann
    Department of Psychiatry, University of Texas Houston Health Science Center, 1300 Moursund Street, Room 270, Houston, TX 77030, USA
    J Affect Disord 67:123-32. 2001
    ..We investigated the structure of manic episodes by determining whether there was evidence for distinct groups of patients differing in clinical characteristics and course of illness...
  33. doi request reprint Antipsychotic withdrawal-induced relapse predicts future relapses in institutionalized adults with severe intellectual disability
    David S Janowsky
    Department of Psychiatry, CB 7175, Medical Research Building A, University of North Carolina, Chapel Hill, NC 27599 7175, USA
    J Clin Psychopharmacol 28:401-5. 2008
    ..Thus, if relapse occurs after an antipsychotic drug withdrawal attempt, subsequent attempts at withdrawal are also very likely to lead to further relapses...
  34. ncbi request reprint Relapse of aggressive and disruptive behavior in mentally retarded adults following antipsychotic drug withdrawal predicts psychotropic drug use a decade later
    David S Janowsky
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7175, USA
    J Clin Psychiatry 67:1272-7. 2006
    ..The purpose of this study was to determine if relapse during or after antipsychotic drug withdrawal in mentally retarded adults predicts continuing antipsychotic drug use an average of a decade later...
  35. ncbi request reprint Antagonism of anticholinesterase (DFP) toxicity by donepezil plus scopolamine: a preliminary study
    David S Janowsky
    Department of Psychiatry, University of North Carolina, CB 7175, Medical Research Building A, Chapel Hill, NC 27599 7175, USA
    Pharmacol Biochem Behav 77:337-43. 2004
    ..Therefore, these preliminary findings are encouraging, but many additional studies are needed to establish the effectiveness of donepezil as a prophylactic agent against irreversible cholinesterase inhibition by DFP...
  36. ncbi request reprint Olanzapine for self-injurious, aggressive, and disruptive behaviors in intellectually disabled adults: a retrospective, open-label, naturalistic trial
    David S Janowsky
    Department of Psychiatry, CB 7175, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7175, USA
    J Clin Psychiatry 64:1258-65. 2003
    ..The effectiveness of olanzapine in treating challenging behaviors in the intellectually disabled and its ability to substitute for conventional antipsychotic drugs were evaluated...
  37. ncbi request reprint A GABAergic cortical deficit dominates schizophrenia pathophysiology
    E Costa
    The Psychiatric Institute, Department of Psychiatry, University of Illinois at Chicago, 1601 W Taylor St, Chicago IL 60612, USA
    Crit Rev Neurobiol 16:1-23. 2004
    ..Hence, imidazenil should be appropriately studied as a prospective candidate for a pharmacological intervention in schizophrenia...
  38. ncbi request reprint Anticholinesterase (DFP) toxicity antagonism by chronic donepezil: a potential nerve agent treatment
    David S Janowsky
    Department of Psychiatry, CB 7175, Medical Research Building A, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7175, USA
    Pharmacol Biochem Behav 81:917-22. 2005
    ..Although these phenomena are not the same as lethality, they may be parallel phenomena, and our results may have therapeutic implications for the treatment of nerve agent toxicity...
  39. ncbi request reprint Minimally effective doses of conventional antipsychotic medications used to treat aggression, self-injurious and destructive behaviors in mentally retarded adults
    David S Janowsky
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7175, USA
    J Clin Psychopharmacol 25:19-25. 2005
    ..3 mg/d and relapse occurred at a mean dose of 93.6 mg/d. The mean lowest effective dose of haloperidol or related high potency drugs (expressed as haloperidol equivalents) was 5.9 mg/d, and relapse occurred at a mean dose of 3.8 mg/d...
  40. pmc The neuropharmacology of psychosis
    Carol A Tamminga
    Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, NE5 110F, Dallas, TX 75390 9127, USA
    Schizophr Bull 33:937-46. 2007
    ..We discuss the kinds of data necessary to further support the dimensional aspects of psychosis...
  41. ncbi request reprint Serotonergic antidepressant effects on aggressive, self-injurious and destructive/disruptive behaviours in intellectually disabled adults: a retrospective, open-label, naturalistic trial
    David S Janowsky
    Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7175, USA
    Int J Neuropsychopharmacol 8:37-48. 2005
    ..The results suggest that serotonergic antidepressants are useful in the treatment of challenging/maladaptive behaviours in the intellectually disabled...
  42. ncbi request reprint A comparative evaluation of three self-rating scales for acute mania
    E Altman
    Psychiatric Institute, University of Illinois at Chicago, 1601 W. Taylor Street, Chicago, IL 60612, USA
    Biol Psychiatry 50:468-71. 2001
    ..All three measures were sensitive to treatment effects; however, the item content of the SRMI and the poor sensitivity of the ISS may limit their utility in inpatient settings...
  43. ncbi request reprint Omega-3 fatty acids: evidence basis for treatment and future research in psychiatry
    Marlene P Freeman
    Women s Mental Health Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson 85724 5002, USA
    J Clin Psychiatry 67:1954-67. 2006
    ..To determine if the available data support the use of omega-3 essential fatty acids (EFA) for clinical use in the prevention and/or treatment of psychiatric disorders...
  44. ncbi request reprint Diagnosis and treatment of depression in patients with mental retardation
    David S Janowsky
    Department of Psychiatry, CB 7175, Medical Research Building A, University of North Carolina, Chapel Hill, NC 27599, USA
    Curr Psychiatry Rep 7:421-8. 2005
    ..This article reviews numerous studies elaborating on the diagnosis, phenomenology, and treatment of depression in mentally retarded individuals...
  45. ncbi request reprint First- and second-generation antipsychotics: learning from CUtLASS and CATIE
    Rajiv Tandon
    Arch Gen Psychiatry 64:977-8; author reply 979-80. 2007
  46. ncbi request reprint The Mount Sinai conference on the pharmacotherapy of schizophrenia
    Stephen R Marder
    VA Desert Pacific Mental Illness Research Education and Clinical Center, West Los Angeles VA Health Care Center, CA 90073, USA
    Schizophr Bull 28:5-16. 2002
    ....
  47. ncbi request reprint All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis
    Charles M Beasley
    Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN 46285, USA
    J Clin Psychopharmacol 27:252-8. 2007
    ..This integrated analysis compared the likelihood of discontinuation from olanzapine treatment versus other antipsychotics among patients with schizophrenia...
  48. ncbi request reprint Physical health monitoring of patients with schizophrenia
    Stephen R Marder
    Department of Veterans Affairs Greater Los Angeles Healthcare System, CA, USA
    Am J Psychiatry 161:1334-49. 2004
    ..The authors discuss a consensus panel's recommendations for improving the physical health monitoring of patients with schizophrenia who are treated in outpatient settings...
  49. pmc Is the superior efficacy of new generation antipsychotics an artifact of LOCF?
    Stefan Leucht
    Klinik für Psychiatrie und Psychotherapie der TU München, Klinikum rechts der Isar, Ismaningerstr 22, 81675 Munchen, Germany
    Schizophr Bull 33:183-91. 2007
    ..Ultimately, strategies to reduce dropout rates are needed...
  50. ncbi request reprint Concomitant medications may not improve outcome of antipsychotic monotherapy for stabilized patients with nonacute schizophrenia
    Ira D Glick
    Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
    J Clin Psychiatry 67:1261-5. 2006
    ..To our knowledge, there have been no published reports of prospective systematic investigations of the efficacy of unrestricted CPM use in nonacute schizophrenia...
  51. ncbi request reprint The costs of drugs for schizophrenia
    Robert Freedman
    Am J Psychiatry 163:2029-31. 2006
  52. ncbi request reprint Switch or stay?
    John M Davis
    Am J Psychiatry 163:2032-3. 2006
  53. ncbi request reprint The choice of drugs for schizophrenia
    John M Davis
    N Engl J Med 354:518-20. 2006
  54. ncbi request reprint Omega-3 fatty acid supplementation in patients with recurrent self-harm. Single-centre double-blind randomised controlled trial
    Brian Hallahan
    Department of Psychiatry, Beaumont Hospital and The Royal College of Surgeons in Ireland, Ireland
    Br J Psychiatry 190:118-22. 2007
    ..Trials have demonstrated benefits of long-chain omega-3 essential fatty acid (n-3 EFA) supplementation in a variety of psychiatric disorders...
  55. ncbi request reprint Defining 'response' in antipsychotic drug trials: recommendations for the use of scale-derived cutoffs
    Stefan Leucht
    Department of Psychiatry and Psychotherapy, Technische Universitat Munchen, Klinikum rechts der Isar, Ismaningerstrasse 22, 81675 Munich, Germany
    Neuropsychopharmacology 32:1903-10. 2007
    ..We suggest a table presenting responder rates in 25 percent steps covering the whole range up to 100% reduction from baseline, which could be displayed together with recently presented criteria for remission...
  56. ncbi request reprint Treating schizophrenia with comorbid depressive or demoralization symptoms
    Ira D Glick
    J Clin Psychiatry 69:501. 2008
  57. ncbi request reprint Does the gerbil model mimic human iron overload?
    Lana Kaiser
    J Lab Clin Med 141:419-20; author reply 420-2. 2003
  58. ncbi request reprint Genetic dissection of fusiform rust and pitch canker disease traits in loblolly pine
    Gogce C Kayihan
    School of Forest Resources and Conservation, University of Florida, PO Box 110410, Gainesville, FL 32611, USA
    Theor Appl Genet 110:948-58. 2005
    ..The disease phenotyping described here is a critical step towards identifying specific loci and alleles associated with fusiform rust and pitch canker resistance...
  59. ncbi request reprint Are there problems with the "time compressed model" of iron overload?
    Lana Kaiser
    J Lab Clin Med 143:130-2; author reply 133-4. 2004
  60. ncbi request reprint Clinical features of 39 patients with antibodies to extractable nuclear antigens despite negative antinuclear antibodies: evidence for autoimmunity including neurologic and connective tissue diseases
    John M Davis
    Division of Rheumatology, Department of Medicine, Mayo Clinic College of Medicine and Mayo Clinic, Rochester, Minnesota 55905, USA
    Medicine (Baltimore) 84:208-17. 2005
    ..This may represent test bias or false-positive anti-ENA assays or false-negative ANA assays, or may imply immune-related mechanisms not previously described...
  61. ncbi request reprint Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury
    Alejandro R Prieto
    Department of Internal Medicine, Division of Cardiology, Michigan State University, East Lansing, MI 48824, USA
    Cardiovasc Res 53:984-92. 2002
    ..We hypothesized that thrombostatin prevents platelet aggregation and adhesion after balloon angioplasty (BA)...
  62. ncbi request reprint Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study
    John M Davis
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 56:820-30. 2007
    ..To determine the relationship between glucocorticoid exposure and cardiovascular (CV) events in patients with rheumatoid arthritis (RA)...
  63. pmc Has research informed us on the practical drug treatment of schizophrenia?
    John M Davis
    Schizophr Bull 34:403-5. 2008
  64. ncbi request reprint Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica
    Hilal Maradit Kremers
    Mayo Clinic, Rochester, Minnesota 55905, USA
    Arthritis Rheum 57:279-86. 2007
    ..To examine the effect of glucocorticoid use on the risk of various cardiovascular diseases in patients with polymyalgia rheumatica (PMR)...